nodes	percent_of_prediction	percent_of_DWPC	metapath
Alosetron—CYP2E1—prostate cancer	0.198	0.614	CbGaD
Alosetron—CYP3A4—prostate cancer	0.124	0.386	CbGaD
Alosetron—CYP2E1—Estrone—prostate cancer	0.0369	0.0841	CbGbCtD
Alosetron—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0355	0.081	CbGbCtD
Alosetron—CYP2C9—Nilutamide—prostate cancer	0.0321	0.0732	CbGbCtD
Alosetron—CYP2C9—Bicalutamide—prostate cancer	0.0321	0.0732	CbGbCtD
Alosetron—CYP1A2—Flutamide—prostate cancer	0.0295	0.0673	CbGbCtD
Alosetron—CYP2E1—Mitoxantrone—prostate cancer	0.0219	0.05	CbGbCtD
Alosetron—CYP1A2—Estrone—prostate cancer	0.0213	0.0487	CbGbCtD
Alosetron—CYP2C9—Estrone—prostate cancer	0.0192	0.0438	CbGbCtD
Alosetron—CYP3A4—Bicalutamide—prostate cancer	0.0187	0.0425	CbGbCtD
Alosetron—CYP3A4—Estramustine—prostate cancer	0.0174	0.0396	CbGbCtD
Alosetron—CYP3A4—Flutamide—prostate cancer	0.0155	0.0353	CbGbCtD
Alosetron—CYP3A4—Abiraterone—prostate cancer	0.0155	0.0353	CbGbCtD
Alosetron—CYP2C9—Capecitabine—prostate cancer	0.0146	0.0332	CbGbCtD
Alosetron—CYP1A2—Conjugated Estrogens—prostate cancer	0.014	0.0318	CbGbCtD
Alosetron—CYP2E1—Etoposide—prostate cancer	0.0138	0.0315	CbGbCtD
Alosetron—CYP1A2—Estradiol—prostate cancer	0.0123	0.0279	CbGbCtD
Alosetron—CYP3A4—Cabazitaxel—prostate cancer	0.0114	0.0261	CbGbCtD
Alosetron—CYP3A4—Estrone—prostate cancer	0.0112	0.0255	CbGbCtD
Alosetron—CYP2C9—Estradiol—prostate cancer	0.011	0.0252	CbGbCtD
Alosetron—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00997	0.0227	CbGbCtD
Alosetron—CYP1A2—Etoposide—prostate cancer	0.008	0.0182	CbGbCtD
Alosetron—CYP3A4—Conjugated Estrogens—prostate cancer	0.00732	0.0167	CbGbCtD
Alosetron—CYP3A4—Mitoxantrone—prostate cancer	0.00665	0.0152	CbGbCtD
Alosetron—CYP3A4—Estradiol—prostate cancer	0.00642	0.0146	CbGbCtD
Alosetron—CYP3A4—Prednisone—prostate cancer	0.00552	0.0126	CbGbCtD
Alosetron—CYP3A4—Etoposide—prostate cancer	0.00419	0.00956	CbGbCtD
Alosetron—CYP3A4—Docetaxel—prostate cancer	0.00384	0.00875	CbGbCtD
Alosetron—CYP3A4—Doxorubicin—prostate cancer	0.00286	0.00652	CbGbCtD
Alosetron—Ondansetron—CYP3A5—prostate cancer	0.00143	0.472	CrCbGaD
Alosetron—Ondansetron—CYP2E1—prostate cancer	0.000985	0.324	CrCbGaD
Alosetron—CYP1A2—urine—prostate cancer	0.000888	0.194	CbGeAlD
Alosetron—CYP2C9—urine—prostate cancer	0.000843	0.184	CbGeAlD
Alosetron—CYP2E1—urine—prostate cancer	0.000799	0.174	CbGeAlD
Alosetron—CYP3A4—urine—prostate cancer	0.000643	0.14	CbGeAlD
Alosetron—Ondansetron—CYP3A4—prostate cancer	0.00062	0.204	CrCbGaD
Alosetron—CYP2E1—prostate gland—prostate cancer	0.000287	0.0625	CbGeAlD
Alosetron—CYP2E1—seminal vesicle—prostate cancer	0.000243	0.0529	CbGeAlD
Alosetron—CYP1A2—renal system—prostate cancer	0.000217	0.0473	CbGeAlD
Alosetron—CYP2E1—renal system—prostate cancer	0.000195	0.0426	CbGeAlD
Alosetron—CYP2E1—urethra—prostate cancer	0.000192	0.0418	CbGeAlD
Alosetron—CYP3A4—renal system—prostate cancer	0.000157	0.0343	CbGeAlD
Alosetron—CYP2E1—testis—prostate cancer	0.000126	0.0275	CbGeAlD
Alosetron—Headache—Ethinyl Estradiol—prostate cancer	9.81e-05	0.00067	CcSEcCtD
Alosetron—Jaundice—Capecitabine—prostate cancer	9.74e-05	0.000665	CcSEcCtD
Alosetron—Urinary tract infection—Capecitabine—prostate cancer	9.71e-05	0.000663	CcSEcCtD
Alosetron—Confusional state—Mitoxantrone—prostate cancer	9.6e-05	0.000656	CcSEcCtD
Alosetron—Hypersensitivity—Goserelin—prostate cancer	9.49e-05	0.000649	CcSEcCtD
Alosetron—Infection—Mitoxantrone—prostate cancer	9.46e-05	0.000646	CcSEcCtD
Alosetron—Hypersensitivity—Conjugated Estrogens—prostate cancer	9.4e-05	0.000642	CcSEcCtD
Alosetron—Muscle spasms—Etoposide—prostate cancer	9.33e-05	0.000637	CcSEcCtD
Alosetron—Haemoglobin—Docetaxel—prostate cancer	9.31e-05	0.000636	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Estradiol—prostate cancer	9.31e-05	0.000636	CcSEcCtD
Alosetron—Nausea—Ethinyl Estradiol—prostate cancer	9.3e-05	0.000635	CcSEcCtD
Alosetron—Eczema—Doxorubicin—prostate cancer	9.3e-05	0.000635	CcSEcCtD
Alosetron—Haemorrhage—Docetaxel—prostate cancer	9.26e-05	0.000633	CcSEcCtD
Alosetron—Hepatitis—Docetaxel—prostate cancer	9.26e-05	0.000633	CcSEcCtD
Alosetron—Hypoglycaemia—Epirubicin—prostate cancer	9.25e-05	0.000632	CcSEcCtD
Alosetron—Asthenia—Goserelin—prostate cancer	9.25e-05	0.000632	CcSEcCtD
Alosetron—Skin disorder—Mitoxantrone—prostate cancer	9.25e-05	0.000632	CcSEcCtD
Alosetron—Hypoaesthesia—Docetaxel—prostate cancer	9.22e-05	0.00063	CcSEcCtD
Alosetron—Hyperhidrosis—Mitoxantrone—prostate cancer	9.2e-05	0.000629	CcSEcCtD
Alosetron—Asthenia—Conjugated Estrogens—prostate cancer	9.16e-05	0.000626	CcSEcCtD
Alosetron—Haemoglobin—Capecitabine—prostate cancer	9.01e-05	0.000616	CcSEcCtD
Alosetron—Hyperglycaemia—Prednisone—prostate cancer	9e-05	0.000615	CcSEcCtD
Alosetron—Ill-defined disorder—Etoposide—prostate cancer	9e-05	0.000615	CcSEcCtD
Alosetron—Haemorrhage—Capecitabine—prostate cancer	8.97e-05	0.000613	CcSEcCtD
Alosetron—Hepatitis—Capecitabine—prostate cancer	8.97e-05	0.000613	CcSEcCtD
Alosetron—Hypoaesthesia—Capecitabine—prostate cancer	8.92e-05	0.00061	CcSEcCtD
Alosetron—Depression—Prednisone—prostate cancer	8.87e-05	0.000606	CcSEcCtD
Alosetron—Fatigue—Estradiol—prostate cancer	8.81e-05	0.000602	CcSEcCtD
Alosetron—Malaise—Etoposide—prostate cancer	8.75e-05	0.000598	CcSEcCtD
Alosetron—Constipation—Estradiol—prostate cancer	8.74e-05	0.000597	CcSEcCtD
Alosetron—Pain—Estradiol—prostate cancer	8.74e-05	0.000597	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	8.67e-05	0.000592	CcSEcCtD
Alosetron—Hypoglycaemia—Doxorubicin—prostate cancer	8.56e-05	0.000585	CcSEcCtD
Alosetron—Cough—Etoposide—prostate cancer	8.47e-05	0.000578	CcSEcCtD
Alosetron—Feeling abnormal—Estradiol—prostate cancer	8.42e-05	0.000575	CcSEcCtD
Alosetron—Hypertension—Etoposide—prostate cancer	8.38e-05	0.000572	CcSEcCtD
Alosetron—Arrhythmia—Docetaxel—prostate cancer	8.27e-05	0.000565	CcSEcCtD
Alosetron—Abdominal pain upper—Epirubicin—prostate cancer	8.25e-05	0.000563	CcSEcCtD
Alosetron—Fatigue—Mitoxantrone—prostate cancer	8.21e-05	0.000561	CcSEcCtD
Alosetron—Vomiting—Goserelin—prostate cancer	8.19e-05	0.00056	CcSEcCtD
Alosetron—Alopecia—Docetaxel—prostate cancer	8.18e-05	0.000559	CcSEcCtD
Alosetron—Discomfort—Etoposide—prostate cancer	8.16e-05	0.000557	CcSEcCtD
Alosetron—Pain—Mitoxantrone—prostate cancer	8.14e-05	0.000556	CcSEcCtD
Alosetron—Constipation—Mitoxantrone—prostate cancer	8.14e-05	0.000556	CcSEcCtD
Alosetron—Rash—Goserelin—prostate cancer	8.13e-05	0.000555	CcSEcCtD
Alosetron—Dermatitis—Goserelin—prostate cancer	8.12e-05	0.000555	CcSEcCtD
Alosetron—Vomiting—Conjugated Estrogens—prostate cancer	8.12e-05	0.000554	CcSEcCtD
Alosetron—Urticaria—Estradiol—prostate cancer	8.12e-05	0.000554	CcSEcCtD
Alosetron—Nasopharyngitis—Epirubicin—prostate cancer	8.07e-05	0.000552	CcSEcCtD
Alosetron—Headache—Goserelin—prostate cancer	8.07e-05	0.000551	CcSEcCtD
Alosetron—Rash—Conjugated Estrogens—prostate cancer	8.05e-05	0.00055	CcSEcCtD
Alosetron—Dermatitis—Conjugated Estrogens—prostate cancer	8.04e-05	0.000549	CcSEcCtD
Alosetron—Haemoglobin—Prednisone—prostate cancer	8.03e-05	0.000548	CcSEcCtD
Alosetron—Arrhythmia—Capecitabine—prostate cancer	8.01e-05	0.000547	CcSEcCtD
Alosetron—Headache—Conjugated Estrogens—prostate cancer	8e-05	0.000546	CcSEcCtD
Alosetron—Gastritis—Epirubicin—prostate cancer	7.99e-05	0.000546	CcSEcCtD
Alosetron—Haemorrhage—Prednisone—prostate cancer	7.99e-05	0.000546	CcSEcCtD
Alosetron—Confusional state—Etoposide—prostate cancer	7.98e-05	0.000545	CcSEcCtD
Alosetron—Alanine aminotransferase increased—Epirubicin—prostate cancer	7.96e-05	0.000544	CcSEcCtD
Alosetron—Alopecia—Capecitabine—prostate cancer	7.92e-05	0.000541	CcSEcCtD
Alosetron—Infection—Etoposide—prostate cancer	7.87e-05	0.000537	CcSEcCtD
Alosetron—Abdominal distension—Epirubicin—prostate cancer	7.86e-05	0.000537	CcSEcCtD
Alosetron—Feeling abnormal—Mitoxantrone—prostate cancer	7.84e-05	0.000536	CcSEcCtD
Alosetron—Muscle spasms—Docetaxel—prostate cancer	7.75e-05	0.00053	CcSEcCtD
Alosetron—Flatulence—Capecitabine—prostate cancer	7.69e-05	0.000525	CcSEcCtD
Alosetron—Skin disorder—Etoposide—prostate cancer	7.69e-05	0.000525	CcSEcCtD
Alosetron—Nausea—Goserelin—prostate cancer	7.65e-05	0.000523	CcSEcCtD
Alosetron—Hyperhidrosis—Etoposide—prostate cancer	7.65e-05	0.000523	CcSEcCtD
Alosetron—Abdominal pain upper—Doxorubicin—prostate cancer	7.63e-05	0.000521	CcSEcCtD
Alosetron—Nausea—Conjugated Estrogens—prostate cancer	7.58e-05	0.000518	CcSEcCtD
Alosetron—Urticaria—Mitoxantrone—prostate cancer	7.56e-05	0.000517	CcSEcCtD
Alosetron—Hypersensitivity—Estradiol—prostate cancer	7.53e-05	0.000514	CcSEcCtD
Alosetron—Muscle spasms—Capecitabine—prostate cancer	7.5e-05	0.000513	CcSEcCtD
Alosetron—Nasopharyngitis—Doxorubicin—prostate cancer	7.47e-05	0.00051	CcSEcCtD
Alosetron—Gastritis—Doxorubicin—prostate cancer	7.39e-05	0.000505	CcSEcCtD
Alosetron—Alanine aminotransferase increased—Doxorubicin—prostate cancer	7.37e-05	0.000503	CcSEcCtD
Alosetron—Asthenia—Estradiol—prostate cancer	7.33e-05	0.000501	CcSEcCtD
Alosetron—Tremor—Capecitabine—prostate cancer	7.31e-05	0.0005	CcSEcCtD
Alosetron—Abdominal distension—Doxorubicin—prostate cancer	7.27e-05	0.000497	CcSEcCtD
Alosetron—Upper respiratory tract infection—Epirubicin—prostate cancer	7.25e-05	0.000496	CcSEcCtD
Alosetron—Ill-defined disorder—Capecitabine—prostate cancer	7.24e-05	0.000495	CcSEcCtD
Alosetron—Pollakiuria—Epirubicin—prostate cancer	7.21e-05	0.000493	CcSEcCtD
Alosetron—Arrhythmia—Prednisone—prostate cancer	7.14e-05	0.000487	CcSEcCtD
Alosetron—Alopecia—Prednisone—prostate cancer	7.06e-05	0.000482	CcSEcCtD
Alosetron—Hyperglycaemia—Epirubicin—prostate cancer	7.04e-05	0.000481	CcSEcCtD
Alosetron—Malaise—Capecitabine—prostate cancer	7.04e-05	0.000481	CcSEcCtD
Alosetron—Cough—Docetaxel—prostate cancer	7.04e-05	0.000481	CcSEcCtD
Alosetron—Hypersensitivity—Mitoxantrone—prostate cancer	7.01e-05	0.000479	CcSEcCtD
Alosetron—Hypertension—Docetaxel—prostate cancer	6.96e-05	0.000476	CcSEcCtD
Alosetron—Myalgia—Docetaxel—prostate cancer	6.86e-05	0.000469	CcSEcCtD
Alosetron—Asthenia—Mitoxantrone—prostate cancer	6.83e-05	0.000467	CcSEcCtD
Alosetron—Fatigue—Etoposide—prostate cancer	6.83e-05	0.000466	CcSEcCtD
Alosetron—Cough—Capecitabine—prostate cancer	6.81e-05	0.000465	CcSEcCtD
Alosetron—Jaundice—Epirubicin—prostate cancer	6.78e-05	0.000463	CcSEcCtD
Alosetron—Pain—Etoposide—prostate cancer	6.77e-05	0.000463	CcSEcCtD
Alosetron—Constipation—Etoposide—prostate cancer	6.77e-05	0.000463	CcSEcCtD
Alosetron—Urinary tract infection—Epirubicin—prostate cancer	6.76e-05	0.000462	CcSEcCtD
Alosetron—Hypertension—Capecitabine—prostate cancer	6.74e-05	0.00046	CcSEcCtD
Alosetron—Dry mouth—Docetaxel—prostate cancer	6.71e-05	0.000459	CcSEcCtD
Alosetron—Upper respiratory tract infection—Doxorubicin—prostate cancer	6.71e-05	0.000458	CcSEcCtD
Alosetron—Sweating—Epirubicin—prostate cancer	6.67e-05	0.000456	CcSEcCtD
Alosetron—Pollakiuria—Doxorubicin—prostate cancer	6.67e-05	0.000456	CcSEcCtD
Alosetron—Myalgia—Capecitabine—prostate cancer	6.65e-05	0.000454	CcSEcCtD
Alosetron—Confusional state—Docetaxel—prostate cancer	6.63e-05	0.000453	CcSEcCtD
Alosetron—Anxiety—Capecitabine—prostate cancer	6.62e-05	0.000452	CcSEcCtD
Alosetron—Discomfort—Capecitabine—prostate cancer	6.57e-05	0.000449	CcSEcCtD
Alosetron—Infection—Docetaxel—prostate cancer	6.54e-05	0.000447	CcSEcCtD
Alosetron—Sinusitis—Epirubicin—prostate cancer	6.53e-05	0.000446	CcSEcCtD
Alosetron—Feeling abnormal—Etoposide—prostate cancer	6.52e-05	0.000446	CcSEcCtD
Alosetron—Hyperglycaemia—Doxorubicin—prostate cancer	6.51e-05	0.000445	CcSEcCtD
Alosetron—Dry mouth—Capecitabine—prostate cancer	6.5e-05	0.000444	CcSEcCtD
Alosetron—Vomiting—Estradiol—prostate cancer	6.5e-05	0.000444	CcSEcCtD
Alosetron—Ill-defined disorder—Prednisone—prostate cancer	6.45e-05	0.000441	CcSEcCtD
Alosetron—Rash—Estradiol—prostate cancer	6.44e-05	0.00044	CcSEcCtD
Alosetron—Dermatitis—Estradiol—prostate cancer	6.44e-05	0.00044	CcSEcCtD
Alosetron—Confusional state—Capecitabine—prostate cancer	6.42e-05	0.000439	CcSEcCtD
Alosetron—Headache—Estradiol—prostate cancer	6.4e-05	0.000437	CcSEcCtD
Alosetron—Skin disorder—Docetaxel—prostate cancer	6.39e-05	0.000437	CcSEcCtD
Alosetron—Infection—Capecitabine—prostate cancer	6.33e-05	0.000432	CcSEcCtD
Alosetron—Urticaria—Etoposide—prostate cancer	6.29e-05	0.00043	CcSEcCtD
Alosetron—Haemoglobin—Epirubicin—prostate cancer	6.28e-05	0.000429	CcSEcCtD
Alosetron—Jaundice—Doxorubicin—prostate cancer	6.28e-05	0.000429	CcSEcCtD
Alosetron—Malaise—Prednisone—prostate cancer	6.27e-05	0.000428	CcSEcCtD
Alosetron—Urinary tract infection—Doxorubicin—prostate cancer	6.26e-05	0.000428	CcSEcCtD
Alosetron—Hepatitis—Epirubicin—prostate cancer	6.25e-05	0.000427	CcSEcCtD
Alosetron—Haemorrhage—Epirubicin—prostate cancer	6.25e-05	0.000427	CcSEcCtD
Alosetron—Hypoaesthesia—Epirubicin—prostate cancer	6.22e-05	0.000425	CcSEcCtD
Alosetron—Skin disorder—Capecitabine—prostate cancer	6.19e-05	0.000423	CcSEcCtD
Alosetron—Sweating—Doxorubicin—prostate cancer	6.17e-05	0.000422	CcSEcCtD
Alosetron—Hyperhidrosis—Capecitabine—prostate cancer	6.16e-05	0.000421	CcSEcCtD
Alosetron—Nausea—Estradiol—prostate cancer	6.07e-05	0.000415	CcSEcCtD
Alosetron—Vomiting—Mitoxantrone—prostate cancer	6.05e-05	0.000413	CcSEcCtD
Alosetron—Sinusitis—Doxorubicin—prostate cancer	6.04e-05	0.000413	CcSEcCtD
Alosetron—Hypertension—Prednisone—prostate cancer	6e-05	0.00041	CcSEcCtD
Alosetron—Rash—Mitoxantrone—prostate cancer	6e-05	0.00041	CcSEcCtD
Alosetron—Dermatitis—Mitoxantrone—prostate cancer	6e-05	0.00041	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Docetaxel—prostate cancer	6e-05	0.00041	CcSEcCtD
Alosetron—Headache—Mitoxantrone—prostate cancer	5.96e-05	0.000407	CcSEcCtD
Alosetron—Myalgia—Prednisone—prostate cancer	5.92e-05	0.000404	CcSEcCtD
Alosetron—Anxiety—Prednisone—prostate cancer	5.9e-05	0.000403	CcSEcCtD
Alosetron—Discomfort—Prednisone—prostate cancer	5.85e-05	0.0004	CcSEcCtD
Alosetron—Hypersensitivity—Etoposide—prostate cancer	5.83e-05	0.000398	CcSEcCtD
Alosetron—Haemoglobin—Doxorubicin—prostate cancer	5.81e-05	0.000397	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Capecitabine—prostate cancer	5.8e-05	0.000397	CcSEcCtD
Alosetron—Haemorrhage—Doxorubicin—prostate cancer	5.78e-05	0.000395	CcSEcCtD
Alosetron—Hepatitis—Doxorubicin—prostate cancer	5.78e-05	0.000395	CcSEcCtD
Alosetron—Hypoaesthesia—Doxorubicin—prostate cancer	5.75e-05	0.000393	CcSEcCtD
Alosetron—Asthenia—Etoposide—prostate cancer	5.68e-05	0.000388	CcSEcCtD
Alosetron—Fatigue—Docetaxel—prostate cancer	5.67e-05	0.000388	CcSEcCtD
Alosetron—Nausea—Mitoxantrone—prostate cancer	5.65e-05	0.000386	CcSEcCtD
Alosetron—Infection—Prednisone—prostate cancer	5.64e-05	0.000385	CcSEcCtD
Alosetron—Pain—Docetaxel—prostate cancer	5.63e-05	0.000384	CcSEcCtD
Alosetron—Constipation—Docetaxel—prostate cancer	5.63e-05	0.000384	CcSEcCtD
Alosetron—Arrhythmia—Epirubicin—prostate cancer	5.58e-05	0.000381	CcSEcCtD
Alosetron—Alopecia—Epirubicin—prostate cancer	5.52e-05	0.000377	CcSEcCtD
Alosetron—Skin disorder—Prednisone—prostate cancer	5.51e-05	0.000377	CcSEcCtD
Alosetron—Fatigue—Capecitabine—prostate cancer	5.49e-05	0.000375	CcSEcCtD
Alosetron—Hyperhidrosis—Prednisone—prostate cancer	5.49e-05	0.000375	CcSEcCtD
Alosetron—Constipation—Capecitabine—prostate cancer	5.45e-05	0.000372	CcSEcCtD
Alosetron—Pain—Capecitabine—prostate cancer	5.45e-05	0.000372	CcSEcCtD
Alosetron—Feeling abnormal—Docetaxel—prostate cancer	5.42e-05	0.00037	CcSEcCtD
Alosetron—Flatulence—Epirubicin—prostate cancer	5.36e-05	0.000366	CcSEcCtD
Alosetron—Feeling abnormal—Capecitabine—prostate cancer	5.25e-05	0.000359	CcSEcCtD
Alosetron—Muscle spasms—Epirubicin—prostate cancer	5.23e-05	0.000357	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Prednisone—prostate cancer	5.17e-05	0.000353	CcSEcCtD
Alosetron—Arrhythmia—Doxorubicin—prostate cancer	5.16e-05	0.000353	CcSEcCtD
Alosetron—Alopecia—Doxorubicin—prostate cancer	5.11e-05	0.000349	CcSEcCtD
Alosetron—Urticaria—Capecitabine—prostate cancer	5.06e-05	0.000346	CcSEcCtD
Alosetron—Ill-defined disorder—Epirubicin—prostate cancer	5.05e-05	0.000345	CcSEcCtD
Alosetron—Vomiting—Etoposide—prostate cancer	5.03e-05	0.000344	CcSEcCtD
Alosetron—Rash—Etoposide—prostate cancer	4.99e-05	0.000341	CcSEcCtD
Alosetron—Dermatitis—Etoposide—prostate cancer	4.99e-05	0.000341	CcSEcCtD
Alosetron—Headache—Etoposide—prostate cancer	4.96e-05	0.000339	CcSEcCtD
Alosetron—Flatulence—Doxorubicin—prostate cancer	4.96e-05	0.000339	CcSEcCtD
Alosetron—Malaise—Epirubicin—prostate cancer	4.9e-05	0.000335	CcSEcCtD
Alosetron—Fatigue—Prednisone—prostate cancer	4.89e-05	0.000334	CcSEcCtD
Alosetron—Constipation—Prednisone—prostate cancer	4.85e-05	0.000332	CcSEcCtD
Alosetron—Hypersensitivity—Docetaxel—prostate cancer	4.85e-05	0.000331	CcSEcCtD
Alosetron—Muscle spasms—Doxorubicin—prostate cancer	4.84e-05	0.00033	CcSEcCtD
Alosetron—Cough—Epirubicin—prostate cancer	4.75e-05	0.000324	CcSEcCtD
Alosetron—Asthenia—Docetaxel—prostate cancer	4.72e-05	0.000323	CcSEcCtD
Alosetron—Nausea—Etoposide—prostate cancer	4.7e-05	0.000321	CcSEcCtD
Alosetron—Hypertension—Epirubicin—prostate cancer	4.7e-05	0.000321	CcSEcCtD
Alosetron—Hypersensitivity—Capecitabine—prostate cancer	4.69e-05	0.000321	CcSEcCtD
Alosetron—Feeling abnormal—Prednisone—prostate cancer	4.68e-05	0.000319	CcSEcCtD
Alosetron—Ill-defined disorder—Doxorubicin—prostate cancer	4.67e-05	0.000319	CcSEcCtD
Alosetron—Myalgia—Epirubicin—prostate cancer	4.63e-05	0.000316	CcSEcCtD
Alosetron—Anxiety—Epirubicin—prostate cancer	4.61e-05	0.000315	CcSEcCtD
Alosetron—Discomfort—Epirubicin—prostate cancer	4.57e-05	0.000312	CcSEcCtD
Alosetron—Asthenia—Capecitabine—prostate cancer	4.57e-05	0.000312	CcSEcCtD
Alosetron—Malaise—Doxorubicin—prostate cancer	4.54e-05	0.00031	CcSEcCtD
Alosetron—Dry mouth—Epirubicin—prostate cancer	4.53e-05	0.000309	CcSEcCtD
Alosetron—Urticaria—Prednisone—prostate cancer	4.51e-05	0.000308	CcSEcCtD
Alosetron—Confusional state—Epirubicin—prostate cancer	4.48e-05	0.000306	CcSEcCtD
Alosetron—Infection—Epirubicin—prostate cancer	4.41e-05	0.000301	CcSEcCtD
Alosetron—Cough—Doxorubicin—prostate cancer	4.39e-05	0.0003	CcSEcCtD
Alosetron—Hypertension—Doxorubicin—prostate cancer	4.34e-05	0.000297	CcSEcCtD
Alosetron—Skin disorder—Epirubicin—prostate cancer	4.31e-05	0.000294	CcSEcCtD
Alosetron—Hyperhidrosis—Epirubicin—prostate cancer	4.29e-05	0.000293	CcSEcCtD
Alosetron—Myalgia—Doxorubicin—prostate cancer	4.28e-05	0.000293	CcSEcCtD
Alosetron—Anxiety—Doxorubicin—prostate cancer	4.27e-05	0.000292	CcSEcCtD
Alosetron—Discomfort—Doxorubicin—prostate cancer	4.23e-05	0.000289	CcSEcCtD
Alosetron—Dry mouth—Doxorubicin—prostate cancer	4.19e-05	0.000286	CcSEcCtD
Alosetron—Vomiting—Docetaxel—prostate cancer	4.18e-05	0.000286	CcSEcCtD
Alosetron—Hypersensitivity—Prednisone—prostate cancer	4.18e-05	0.000286	CcSEcCtD
Alosetron—Rash—Docetaxel—prostate cancer	4.15e-05	0.000283	CcSEcCtD
Alosetron—Dermatitis—Docetaxel—prostate cancer	4.15e-05	0.000283	CcSEcCtD
Alosetron—Confusional state—Doxorubicin—prostate cancer	4.14e-05	0.000283	CcSEcCtD
Alosetron—Headache—Docetaxel—prostate cancer	4.12e-05	0.000282	CcSEcCtD
Alosetron—Infection—Doxorubicin—prostate cancer	4.08e-05	0.000279	CcSEcCtD
Alosetron—Asthenia—Prednisone—prostate cancer	4.07e-05	0.000278	CcSEcCtD
Alosetron—Vomiting—Capecitabine—prostate cancer	4.05e-05	0.000277	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.04e-05	0.000276	CcSEcCtD
Alosetron—Rash—Capecitabine—prostate cancer	4.02e-05	0.000274	CcSEcCtD
Alosetron—Dermatitis—Capecitabine—prostate cancer	4.01e-05	0.000274	CcSEcCtD
Alosetron—Headache—Capecitabine—prostate cancer	3.99e-05	0.000273	CcSEcCtD
Alosetron—Skin disorder—Doxorubicin—prostate cancer	3.99e-05	0.000272	CcSEcCtD
Alosetron—Hyperhidrosis—Doxorubicin—prostate cancer	3.97e-05	0.000271	CcSEcCtD
Alosetron—Nausea—Docetaxel—prostate cancer	3.91e-05	0.000267	CcSEcCtD
Alosetron—Fatigue—Epirubicin—prostate cancer	3.83e-05	0.000261	CcSEcCtD
Alosetron—Constipation—Epirubicin—prostate cancer	3.8e-05	0.000259	CcSEcCtD
Alosetron—Pain—Epirubicin—prostate cancer	3.8e-05	0.000259	CcSEcCtD
Alosetron—Nausea—Capecitabine—prostate cancer	3.78e-05	0.000259	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.74e-05	0.000256	CcSEcCtD
Alosetron—Feeling abnormal—Epirubicin—prostate cancer	3.66e-05	0.00025	CcSEcCtD
Alosetron—Vomiting—Prednisone—prostate cancer	3.61e-05	0.000246	CcSEcCtD
Alosetron—Rash—Prednisone—prostate cancer	3.58e-05	0.000244	CcSEcCtD
Alosetron—Dermatitis—Prednisone—prostate cancer	3.57e-05	0.000244	CcSEcCtD
Alosetron—Headache—Prednisone—prostate cancer	3.56e-05	0.000243	CcSEcCtD
Alosetron—Fatigue—Doxorubicin—prostate cancer	3.54e-05	0.000242	CcSEcCtD
Alosetron—Urticaria—Epirubicin—prostate cancer	3.53e-05	0.000241	CcSEcCtD
Alosetron—Constipation—Doxorubicin—prostate cancer	3.51e-05	0.00024	CcSEcCtD
Alosetron—Pain—Doxorubicin—prostate cancer	3.51e-05	0.00024	CcSEcCtD
Alosetron—Feeling abnormal—Doxorubicin—prostate cancer	3.38e-05	0.000231	CcSEcCtD
Alosetron—Nausea—Prednisone—prostate cancer	3.37e-05	0.00023	CcSEcCtD
Alosetron—Hypersensitivity—Epirubicin—prostate cancer	3.27e-05	0.000223	CcSEcCtD
Alosetron—Urticaria—Doxorubicin—prostate cancer	3.26e-05	0.000223	CcSEcCtD
Alosetron—Asthenia—Epirubicin—prostate cancer	3.18e-05	0.000218	CcSEcCtD
Alosetron—Hypersensitivity—Doxorubicin—prostate cancer	3.03e-05	0.000207	CcSEcCtD
Alosetron—Asthenia—Doxorubicin—prostate cancer	2.95e-05	0.000201	CcSEcCtD
Alosetron—Vomiting—Epirubicin—prostate cancer	2.82e-05	0.000193	CcSEcCtD
Alosetron—Rash—Epirubicin—prostate cancer	2.8e-05	0.000191	CcSEcCtD
Alosetron—Dermatitis—Epirubicin—prostate cancer	2.8e-05	0.000191	CcSEcCtD
Alosetron—Headache—Epirubicin—prostate cancer	2.78e-05	0.00019	CcSEcCtD
Alosetron—Nausea—Epirubicin—prostate cancer	2.64e-05	0.00018	CcSEcCtD
Alosetron—Vomiting—Doxorubicin—prostate cancer	2.61e-05	0.000178	CcSEcCtD
Alosetron—Rash—Doxorubicin—prostate cancer	2.59e-05	0.000177	CcSEcCtD
Alosetron—Dermatitis—Doxorubicin—prostate cancer	2.59e-05	0.000177	CcSEcCtD
Alosetron—Headache—Doxorubicin—prostate cancer	2.57e-05	0.000176	CcSEcCtD
Alosetron—Nausea—Doxorubicin—prostate cancer	2.44e-05	0.000167	CcSEcCtD
Alosetron—CYP3A4—Metabolism—HPGD—prostate cancer	7.58e-06	8.89e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTA1—prostate cancer	7.49e-06	8.79e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—TCN2—prostate cancer	7.44e-06	8.73e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTA3—prostate cancer	7.44e-06	8.73e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—UCP3—prostate cancer	7.44e-06	8.73e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PDHA1—prostate cancer	7.44e-06	8.73e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTO1—prostate cancer	7.4e-06	8.69e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—HSD3B2—prostate cancer	7.4e-06	8.69e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—NAT2—prostate cancer	7.4e-06	8.69e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—NCOA2—prostate cancer	7.36e-06	8.64e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—TNFRSF21—prostate cancer	7.12e-06	8.36e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	7.12e-06	8.35e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—HSD3B1—prostate cancer	7.1e-06	8.33e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—SLC22A3—prostate cancer	7.1e-06	8.33e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PLCB2—prostate cancer	7.1e-06	8.33e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—LRP2—prostate cancer	7.1e-06	8.33e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CYP2C18—prostate cancer	7.1e-06	8.33e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—SLC5A5—prostate cancer	7.02e-06	8.24e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—P4HB—prostate cancer	6.96e-06	8.17e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CYP7B1—prostate cancer	6.93e-06	8.13e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—MTAP—prostate cancer	6.93e-06	8.13e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—LPL—prostate cancer	6.89e-06	8.08e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—TBXAS1—prostate cancer	6.8e-06	7.98e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTA4—prostate cancer	6.8e-06	7.98e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—NQO1—prostate cancer	6.78e-06	7.96e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—SLC22A1—prostate cancer	6.77e-06	7.95e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—SULT1E1—prostate cancer	6.75e-06	7.92e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—SRD5A1—prostate cancer	6.75e-06	7.92e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	6.69e-06	7.85e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—TH—prostate cancer	6.68e-06	7.84e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	6.65e-06	7.8e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTA2—prostate cancer	6.63e-06	7.78e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CYP3A4—prostate cancer	6.61e-06	7.76e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—SULT2A1—prostate cancer	6.6e-06	7.74e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—SULT1A1—prostate cancer	6.55e-06	7.69e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ABCG5—prostate cancer	6.55e-06	7.69e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CYP1B1—prostate cancer	6.5e-06	7.63e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—MED12—prostate cancer	6.49e-06	7.62e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ACSL4—prostate cancer	6.44e-06	7.56e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—HSD17B3—prostate cancer	6.44e-06	7.56e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GNG5—prostate cancer	6.44e-06	7.56e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTA1—prostate cancer	6.4e-06	7.51e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—HSD3B2—prostate cancer	6.33e-06	7.42e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTO1—prostate cancer	6.33e-06	7.42e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—NAT2—prostate cancer	6.33e-06	7.42e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GGT1—prostate cancer	6.3e-06	7.39e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—NCOA3—prostate cancer	6.2e-06	7.28e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—NCOA1—prostate cancer	6.2e-06	7.28e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PHGDH—prostate cancer	6.18e-06	7.25e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—UMPS—prostate cancer	6.18e-06	7.25e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ARG2—prostate cancer	6.18e-06	7.25e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CYP19A1—prostate cancer	6.11e-06	7.17e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	6.1e-06	7.15e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	6.08e-06	7.14e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—LRP2—prostate cancer	6.06e-06	7.12e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PLCB2—prostate cancer	6.06e-06	7.12e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CYP2C18—prostate cancer	6.06e-06	7.12e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—LDHB—prostate cancer	6.06e-06	7.11e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—P4HB—prostate cancer	5.95e-06	6.98e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CYP3A5—prostate cancer	5.95e-06	6.98e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—HPGDS—prostate cancer	5.92e-06	6.94e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—RXRA—prostate cancer	5.9e-06	6.92e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CYP2C19—prostate cancer	5.88e-06	6.9e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—SLC22A1—prostate cancer	5.79e-06	6.79e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—UCP3—prostate cancer	5.74e-06	6.74e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTA3—prostate cancer	5.74e-06	6.74e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—TCN2—prostate cancer	5.74e-06	6.74e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PDHA1—prostate cancer	5.74e-06	6.74e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTT1—prostate cancer	5.74e-06	6.74e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ACHE—prostate cancer	5.74e-06	6.74e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	5.72e-06	6.71e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—COMT—prostate cancer	5.68e-06	6.67e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CYP2A6—prostate cancer	5.67e-06	6.66e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GSTP1—prostate cancer	5.66e-06	6.64e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	5.65e-06	6.63e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—SULT2A1—prostate cancer	5.64e-06	6.62e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ITPR1—prostate cancer	5.57e-06	6.53e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—MED12—prostate cancer	5.55e-06	6.51e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—AKR1C3—prostate cancer	5.52e-06	6.48e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GNG5—prostate cancer	5.5e-06	6.46e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PRKACB—prostate cancer	5.49e-06	6.44e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—HSD3B1—prostate cancer	5.48e-06	6.43e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—SLC22A3—prostate cancer	5.48e-06	6.43e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CYP17A1—prostate cancer	5.43e-06	6.38e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	5.36e-06	6.29e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—NCOA3—prostate cancer	5.3e-06	6.22e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—TYMS—prostate cancer	5.26e-06	6.17e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTA4—prostate cancer	5.25e-06	6.16e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—TBXAS1—prostate cancer	5.25e-06	6.16e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	5.21e-06	6.11e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GSTM1—prostate cancer	5.2e-06	6.1e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—NCOA2—prostate cancer	5.18e-06	6.08e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTA2—prostate cancer	5.12e-06	6.01e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—LPL—prostate cancer	5.1e-06	5.99e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—HPGDS—prostate cancer	5.06e-06	5.93e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ABCG5—prostate cancer	5.06e-06	5.93e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—SULT1A1—prostate cancer	5.06e-06	5.93e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CYP2C19—prostate cancer	5.03e-06	5.9e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—SLC5A5—prostate cancer	4.94e-06	5.8e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTA1—prostate cancer	4.94e-06	5.79e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CYP1A1—prostate cancer	4.93e-06	5.78e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ACHE—prostate cancer	4.91e-06	5.76e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTT1—prostate cancer	4.91e-06	5.76e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ERCC2—prostate cancer	4.89e-06	5.73e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—NAT2—prostate cancer	4.88e-06	5.73e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTO1—prostate cancer	4.88e-06	5.73e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—HSD3B2—prostate cancer	4.88e-06	5.73e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CYP2A6—prostate cancer	4.85e-06	5.69e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	4.83e-06	5.67e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CYP2E1—prostate cancer	4.82e-06	5.66e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—NQO1—prostate cancer	4.77e-06	5.6e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—AKR1C3—prostate cancer	4.72e-06	5.53e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—TH—prostate cancer	4.7e-06	5.52e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PRKACB—prostate cancer	4.69e-06	5.51e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—LRP2—prostate cancer	4.68e-06	5.49e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PLCB2—prostate cancer	4.68e-06	5.49e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CYP2C18—prostate cancer	4.68e-06	5.49e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	4.67e-06	5.48e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CYP3A4—prostate cancer	4.65e-06	5.46e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CYP17A1—prostate cancer	4.64e-06	5.45e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	4.63e-06	5.43e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—MTHFR—prostate cancer	4.59e-06	5.39e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—P4HB—prostate cancer	4.59e-06	5.39e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	4.58e-06	5.37e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CYP1B1—prostate cancer	4.57e-06	5.37e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PPARA—prostate cancer	4.51e-06	5.29e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—SLC22A1—prostate cancer	4.47e-06	5.24e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GGT1—prostate cancer	4.43e-06	5.2e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—NCOA2—prostate cancer	4.42e-06	5.19e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—NCOA1—prostate cancer	4.36e-06	5.12e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—SULT2A1—prostate cancer	4.35e-06	5.11e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CYP19A1—prostate cancer	4.3e-06	5.05e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—MED12—prostate cancer	4.28e-06	5.02e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GNG5—prostate cancer	4.25e-06	4.98e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CAV1—prostate cancer	4.24e-06	4.97e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—SLC5A5—prostate cancer	4.22e-06	4.95e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—RXRA—prostate cancer	4.15e-06	4.87e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CYP2E1—prostate cancer	4.12e-06	4.84e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—NCOA3—prostate cancer	4.09e-06	4.8e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—NQO1—prostate cancer	4.08e-06	4.78e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	4.04e-06	4.74e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—TH—prostate cancer	4.02e-06	4.71e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—COMT—prostate cancer	4e-06	4.69e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	3.99e-06	4.68e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTP1—prostate cancer	3.98e-06	4.67e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CYP3A4—prostate cancer	3.98e-06	4.66e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.96e-06	4.64e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ITPR1—prostate cancer	3.91e-06	4.59e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CYP1B1—prostate cancer	3.91e-06	4.59e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—HPGDS—prostate cancer	3.9e-06	4.58e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CYP2C19—prostate cancer	3.88e-06	4.55e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PIK3CG—prostate cancer	3.86e-06	4.53e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.85e-06	4.52e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTT1—prostate cancer	3.79e-06	4.44e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ACHE—prostate cancer	3.79e-06	4.44e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GGT1—prostate cancer	3.79e-06	4.44e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CYP2A6—prostate cancer	3.74e-06	4.39e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—NCOA1—prostate cancer	3.73e-06	4.37e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—TYMS—prostate cancer	3.7e-06	4.34e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CYP19A1—prostate cancer	3.67e-06	4.31e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTM1—prostate cancer	3.66e-06	4.29e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—INS—prostate cancer	3.65e-06	4.29e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—AKR1C3—prostate cancer	3.64e-06	4.27e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PRKACB—prostate cancer	3.62e-06	4.25e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—LPL—prostate cancer	3.59e-06	4.21e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CYP17A1—prostate cancer	3.58e-06	4.2e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CREBBP—prostate cancer	3.58e-06	4.2e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—RXRA—prostate cancer	3.55e-06	4.16e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CYP1A1—prostate cancer	3.47e-06	4.07e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.45e-06	4.05e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ERCC2—prostate cancer	3.44e-06	4.03e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—COMT—prostate cancer	3.42e-06	4.01e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—NCOA2—prostate cancer	3.41e-06	4.01e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTP1—prostate cancer	3.4e-06	3.99e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PIK3CD—prostate cancer	3.39e-06	3.98e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ITPR1—prostate cancer	3.35e-06	3.93e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.29e-06	3.86e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—SLC5A5—prostate cancer	3.26e-06	3.82e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—MTHFR—prostate cancer	3.23e-06	3.79e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—NOS3—prostate cancer	3.2e-06	3.76e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CYP2E1—prostate cancer	3.18e-06	3.73e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PPARA—prostate cancer	3.17e-06	3.72e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—TYMS—prostate cancer	3.16e-06	3.71e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—NQO1—prostate cancer	3.15e-06	3.69e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTM1—prostate cancer	3.12e-06	3.67e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—TH—prostate cancer	3.1e-06	3.64e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—LPL—prostate cancer	3.07e-06	3.6e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CYP1B1—prostate cancer	3.02e-06	3.54e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CAV1—prostate cancer	2.98e-06	3.5e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CYP1A1—prostate cancer	2.96e-06	3.48e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PIK3CB—prostate cancer	2.96e-06	3.47e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ERCC2—prostate cancer	2.94e-06	3.45e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PTGS2—prostate cancer	2.93e-06	3.44e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GGT1—prostate cancer	2.92e-06	3.43e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—NCOA1—prostate cancer	2.88e-06	3.38e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.85e-06	3.34e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.84e-06	3.33e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—MTHFR—prostate cancer	2.76e-06	3.24e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—RXRA—prostate cancer	2.74e-06	3.21e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PIK3CG—prostate cancer	2.71e-06	3.19e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PPARA—prostate cancer	2.71e-06	3.18e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—COMT—prostate cancer	2.64e-06	3.09e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTP1—prostate cancer	2.62e-06	3.08e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ITPR1—prostate cancer	2.58e-06	3.03e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—INS—prostate cancer	2.57e-06	3.02e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PTEN—prostate cancer	2.56e-06	3e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CAV1—prostate cancer	2.55e-06	2.99e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CREBBP—prostate cancer	2.52e-06	2.95e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—TYMS—prostate cancer	2.44e-06	2.86e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—EP300—prostate cancer	2.44e-06	2.86e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.43e-06	2.86e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTM1—prostate cancer	2.41e-06	2.83e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PIK3CD—prostate cancer	2.39e-06	2.8e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—LPL—prostate cancer	2.37e-06	2.78e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PIK3CG—prostate cancer	2.32e-06	2.72e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.29e-06	2.68e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ERCC2—prostate cancer	2.27e-06	2.66e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—NOS3—prostate cancer	2.25e-06	2.64e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—INS—prostate cancer	2.2e-06	2.58e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CREBBP—prostate cancer	2.15e-06	2.52e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—MTHFR—prostate cancer	2.13e-06	2.5e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PPARA—prostate cancer	2.09e-06	2.45e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PIK3CB—prostate cancer	2.08e-06	2.44e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PTGS2—prostate cancer	2.06e-06	2.42e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PIK3CD—prostate cancer	2.04e-06	2.39e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CAV1—prostate cancer	1.97e-06	2.31e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—NOS3—prostate cancer	1.93e-06	2.26e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PIK3CA—prostate cancer	1.8e-06	2.12e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PTEN—prostate cancer	1.8e-06	2.11e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.79e-06	2.1e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PIK3CB—prostate cancer	1.78e-06	2.09e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PTGS2—prostate cancer	1.76e-06	2.07e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—EP300—prostate cancer	1.71e-06	2.01e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—INS—prostate cancer	1.69e-06	1.99e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CREBBP—prostate cancer	1.66e-06	1.95e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.57e-06	1.85e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PTEN—prostate cancer	1.54e-06	1.8e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—NOS3—prostate cancer	1.49e-06	1.74e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—AKT1—prostate cancer	1.47e-06	1.73e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—EP300—prostate cancer	1.46e-06	1.72e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.37e-06	1.61e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PTGS2—prostate cancer	1.36e-06	1.6e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PIK3CA—prostate cancer	1.27e-06	1.49e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PTEN—prostate cancer	1.19e-06	1.39e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—EP300—prostate cancer	1.13e-06	1.33e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PIK3CA—prostate cancer	1.08e-06	1.27e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—AKT1—prostate cancer	1.04e-06	1.22e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—AKT1—prostate cancer	8.85e-07	1.04e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PIK3CA—prostate cancer	8.36e-07	9.81e-06	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—AKT1—prostate cancer	6.83e-07	8.02e-06	CbGpPWpGaD
